ArticleCancer research2013
Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 66 citations in OpenAlex.
- Whole Genome-Derived Tiled Peptide Arrays Detect Prediagnostic Autoantibody Signatures in Non-Small-Cell Lung Cancer.Cancer research · 2019Trial
- Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.Journal of hematology & oncology · 2013Trial
- Novel radiation-derived gene blueprint stratifying patients with breast cancer.Discover oncology · 2025Article
- Article
- Development of high-titer class-switched antibody responses to phosphorylated amino acids is prevalent in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2025Article
- Dissecting the multifaceted roles of autophagy in cancer initiation, growth, and metastasis: from molecular mechanisms to therapeutic applications.Medical oncology (Northwood, London, England) · 2024Review
- Tumor-Associated and Systemic Autoimmunity in Pre-Clinical Breast Cancer among Post-Menopausal Women.Biomolecules · 2023Article
- Cancer-Associated B Cells in Sarcoma.Cancers · 2023Review
- Three unconventional maxims in the natural selection of cancer cells: Generation of induced tumor-suppressing cells (iTSCs).International journal of biological sciences · 2023Review
- The Autoantibodies against Tumor-Associated Antigens as Potential Blood-Based Biomarkers in Thyroid Neoplasia: Rationales, Opportunities and Challenges.Biomedicines · 2022Review
- High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.Cancer science · 2022Article
- Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis.Frontiers in cell and developmental biology · 2022Article
- Autoantibodies as biomarkers for breast cancer diagnosis and prognosis.Frontiers in immunology · 2022Review
- Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies.International journal of molecular sciences · 2021Article
- Identification of novel autoantibody signatures and evaluation of a panel of autoantibodies in breast cancer.Cancer science · 2021Article
- Autoantibody profiles and clinical association in Thai patients with autoimmune retinopathy.Scientific reports · 2021Article
- Protein citrullination as a source of cancer neoantigens.Journal for immunotherapy of cancer · 2021Article
- Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients.NPJ breast cancer · 2021Article
- The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves.Statistics in medicine · 2021Article
- Enhanced humoral immunity in breast cancer patients with high serum concentration of anti-HER2 autoantibody.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
We assessed the autoantibody repertoire of a mouse model engineered to develop breast cancer and the repertoire of autoantibodies in human plasmas collected at a preclinical time point and at the time of clinical diagnosis of breast cancer. In seeking to identify common pathways, networks, and protein families associated with the humoral response, we elucidated the dynamic nature of tumor antigens and autoantibody interactions. Lysate proteins from an immortalized cell line from a MMTV-neu mouse model and from MCF7 human breast cancers were spotted onto nitrocellulose microarrays and hybridized with mouse and human plasma samples, respectively. Immunoglobulin-based plasma immunoreactivity against glycolysis and spliceosome proteins was a predominant feature observed both in tumor-bearing mice and in prediagnostic human samples. Interestingly, autoantibody reactivity was more pronounced further away than closer to diagnosis. We provide evidence for dynamic changes in autoantibody reactivity with tumor development and progression that may depend, in part, on the extent of antigen-antibody interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.